IMOPHORON
Imophoron is the developer of a novel next-generation rapid-response vaccine platform, ADDomer(TM).
IMOPHORON
Industry:
Biotechnology Life Science Therapeutics
Founded:
2017-01-01
Address:
Bristol, Bristol, City Of, United Kingdom
Country:
United Kingdom
Total Employee:
1+
Status:
Active
Total Funding:
4 M GBP
Similar Organizations
ATAI Life Sciences
ATAI Life Sciences develops innovative mental health treatments that address significant unmet medical needs.
Autobahn Therapeutics
Autobahn Therapeutics is a developer of regenerative medicines to restore hope for people affected by CNS disorders.
Menten AI
Menten AI develops peptide and protein therapeutics using machine learning and quantum computing.
Slingshot Biosciences
Slingshot Biosciences develops next-generation synthetic cells for diagnostics and therapeutics.
Current Employees Featured
Founder
Investors List
Science Creates Ventures
Science Creates Ventures investment in Seed Round - Imophoron
Jonathan Milner
Jonathan Milner investment in Seed Round - Imophoron
Octopus Ventures
Octopus Ventures investment in Seed Round - Imophoron
More informations about "Imophoron"
Imophoron - discover.ukri.org
Imophoron’s ADDomerâ„¢ platform is facilitating the development of new vaccines to treat human and animal diseases The company was co-founded by Imre Berger, Professor of Biochemistry at the University of Bristol, and Mr Frédéric …See details»
Imophoron - Crunchbase Company Profile & Funding
Oct 7, 2021 Imophoron is the developer of a novel next-generation rapid-response vaccine platform, ADDomer(TM).See details»
Imophoron 2025 Company Profile: Valuation, Funding & Investors
Information on valuation, funding, cap tables, investors, and executives for Imophoron. Use the PitchBook Platform to explore the full profile.See details»
Imophoron - Executive Bio, Top Executies, and Transitions - Equilar ...
View the organization profile of Imophoron,Richard was formerly Chief Executive Officer of AIM-listed Diurnal Group plc, where he led the sale of the company to Neurocrine Biosciences in …See details»
Member profile: Imophoron Limited | BIA
About Imophoron Limited Imophoron was founded in 2017 and is based at Science Creates in Bristol, UK. Imophoron has developed a novel next-generation nanoparticle platform, …See details»
Imophoron Ltd - Bristol, United Kingdom - bionity.com
Imophoron was founded in 2017 and is based at Science Creates in Bristol, UK. Imophoron has developed a novel next-generation nanoparticle platform, ADDomerâ„¢, initially focused on the development of vaccines to combat …See details»
Imophoron Ltd. - Drug pipelines, Patents, Clinical trials - Synapse
Jul 16, 2023 He is currently Chair of the Board of Directors for Circio Holding ASA, Imophoron Ltd, and Indegra Therapeutics Ltd. Marc Le Bozec is a life sciences entrepreneur with a strong …See details»
Imophoron - Octopus Investments
Imophoron also intend to deliver vaccines intranasally, providing an over-the-counter nasal spray alternative to injections for common viruses such as the flu. Currently vaccines need to be …See details»
Imophoron - VentureRadar
"Imophoron is developing a novel vaccine platform for use on emerging infectious diseases. The platform is based on a single component of the human Adenovirus that spontaneously forms a …See details»
Imophoron - sciencecreates.co.uk
Imophoron developed a new class of synthetic vaccine to tackle emerging infectious diseases. Its novel platform was based a single component of the human Adenovirus that spontaneously …See details»
Imophoron - Products, Competitors, Financials, Employees, …
Imophoron is a biotechnology company focused on the development of next-generation vaccines for unmet medical needs and future threats. The company's main offering is the creation of …See details»
Global Brain has invested in Imophoron Limited, a biotech startup ...
Jul 6, 2023 Global Brain has invested in Imophoron Limited (Imophoron), a biotech startup developing novel vaccines using the ADDomerâ„¢ platform, through its Meiji Yasuda Future …See details»
Our investment in Imophoron - Octopus Ventures
Oct 20, 2021 The team combines decades of experience in the biotech space with significant commercial and startup expertise. While Imophoron is still principally involved in technology …See details»
Imophoron - News & Analysis - Crunchbase
Aug 22, 2023 Imophoron is the developer of a novel next-generation rapid-response vaccine platform, ADDomer(TM).See details»
5 questions to Frederic Garzoni, CEO and founder of Imophoron ...
Feb 1, 2022 5 questions to Frederic Garzoni, CEO and founder of Imophoron Ltd [fr] Frederic Garzoni is a French scientist and entrepreneur living in Bristol, where he founded Imophoron, …See details»
Imophoron | VentureRadar
Imophoron is developing a novel vaccine platform for use on emerging infectious diseases. The platform is based on a single component of the human Adenovirus that spontaneously forms a …See details»
Imophoron | | The Pharmaletter | The Pharmaletter
Imophoron A biotech company developing a novel next-generation rapid-response vaccine platform. Imophoron was founded in 2017 and since has developed a novel next-generation …See details»
Imophoron - F6S
Imophoron - We are a pre-clinical stage company with a novel next generation nanoparticle vaccine platform called ADDomerâ„¢. ADDomerâ„¢ is a patented technology for creating highly …See details»
Imophoron - Financial Details - Crunchbase
Imophoron is the developer of a novel next-generation rapid-response vaccine platform, ADDomer(TM).See details»
Imophoron - Growth Outlook - Crunchbase
Imophoron is the developer of a novel next-generation rapid-response vaccine platform, ADDomer(TM).See details»